Roluperidone Relapse Prevention for Schizophrenia Negative Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia, particularly those targeting negative symptoms, often interfere with dopamine neurotransmission, leading to secondary negative symptoms like Parkinsonism and sedation, and there are no approved treatments for preventing relapse in schizophrenia patients in the United States.
Innovation Solution
Administering Roluperidone, a novel cyclic amido derivative with selective receptor antagonism, to schizophrenia patients with stable moderate to severe negative symptoms to prevent relapse.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments are used to target negative symptoms, then symptom improvement may be achieved, but secondary negative symptoms like Parkinsonism and sedation occur due to dopamine neurotransmission interference
Solution Approach 1:
The invention changes the pharmacological parameters by using Roluperidone with a distinct receptor binding profile (5-HT2A, sigma2, α1A-adrenergic) compared to conventional antipsychotics. This parameter change allows treatment of negative symptoms without blocking dopamine receptors, thereby avoiding Parkinsonism and sedation while maintaining therapeutic effectiveness
Solution Approach 2:
Roluperidone acts as a composite pharmacological agent with multiple receptor antagonistic activities (5-HT2A, sigma2, α1A-adrenergic) working together to treat negative symptoms through a multifaceted mechanism that bypasses the dopamine pathway, thus achieving symptom improvement without the harmful side effects of traditional monomodal dopamine antagonists
2Reliability
If Roluperidone is administered to prevent relapse, then the risk of relapse is reduced and functional outcomes are maintained, but the dosage and frequency must be optimized to avoid under or over treatment
Solution Approach 1:
The invention establishes specific dosage parameters (1-100 mg daily, administered once or twice daily) that optimize relapse prevention effectiveness. These parameter specifications provide clear dosing guidance that balances therapeutic benefit with safety, reducing the complexity of dosage optimization while maintaining high reliability in relapse prevention
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This application pertains to methods of preventing relapse in schizophrenia patients that include administering a therapeutically effective amount of Roluperidone to the schizophrenia patient.